Sarepta CEO Douglas Ingram to retire by end of 2026; successor search underway

Sarepta Therapeutics, Inc.

CEO Douglas Ingram notified retirement by end of 2026 or upon appointment of replacement.
Board has commenced search for successor, considering internal and external candidates.
Ingram will remain CEO until successor is appointed or through 2026.

item 5.02

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-072064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.